Previous Section Index Home Page

14 July 2008 : Column 206W—continued

NHS: Land

Mr. Pickles: To ask the Secretary of State for Health (1) what assessment he has made of the effect of the downturn in the property market on the financial position of NHS trusts which have factored in profits from the sale of surplus land into their budgets; [217791]

(2) what requirements NHS trusts have to notify his Department of surplus land sales; and what consent regimes exist to authorise the disposal of surplus land; [217792]

(3) what guidance his Department has provided to NHS trusts on the disposal of surplus land. [217793]

Mr. Bradshaw: National health service trusts develop and manage their own capital financing plans, to which the proceeds from property disposals may make a contribution. Such transactions are subject to the conditions of the property market at that time. In general, a more significant contribution is made from the cash they receive in their income for the depreciation charge in their accounts, through loans from the Department and, under certain circumstances, allocations of public dividend capital. It is for NHS trusts to manage any changes in value of proceeds from asset disposals as part of their capital and overall financial planning

The Department operates a system of delegated limits for capital investment and for property transactions for NHS trusts, primary care trusts and strategic health authorities. A copy of the Delegated Limits for Capital Investment guidance has been placed in the Library.

Guidance to NHS organisations on all land and property transactions, including the disposal of surplus land or buildings, is given in the Department’s publication, Health Building Note 00-08: “Estatecode”, copies of which have been placed in the Library.

Under this guidance, where property has been identified as surplus to a particular NHS organisation, it should be offered to other local trusts to determine whether the asset could be re-used by them for the provision of healthcare services, Government Departments and the local authority. This policy accords with the Government’s requirement to make better use of surplus public sector land.

NHS foundation trusts are authorised and regulated by Monitor, the independent regulator, which provides guidance to these trusts on property transactions.


14 July 2008 : Column 207W

NHS: Procurement

Mr. Lansley: To ask the Secretary of State for Health in which areas primary care trust commissioning is immature, as referred to on page 10 of his Department's document, Developing the NHS Performance Regime, published on 4 June 2008. [216907]

Mr. Bradshaw: Commissioning for local health services in England is the core responsibility of primary care trusts (PCTs). It is a complex process with responsibilities ranging from assessing population needs and prioritising health outcomes to procuring products and services, and managing service providers. As such, commissioners are required to possess a wide range of skills, including robust analysis, effective stakeholder engagement and communication, financial management, strategic planning and performance management skills. The joint Department of Health and Prime Minister's Delivery Unit review of commissioning capabilities in May 2007 suggested that some PCTs perform better in some areas than others. However, there is not yet any comprehensive evidence about commissioning strengths and weaknesses nationally.

In June this year, a national commissioning assurance system was launched to hold commissioners to account through assessing their performance and rewarding development. PCTs will be assessed against commissioning skill sets, or competencies, organisational governance and health outcomes. By publishing and assessing against the competencies that make commissioning for health services world class, a clearer national picture will emerge. PCTs will also be better able to understand where their commissioning strengths and weaknesses lie and will be incentivised to access support and development resources in order to improve.

NHS: Public Appointments

Mr. Oaten: To ask the Secretary of State for Health when he expects to make a full-time appointment to the post of head of the NHS Commercial Directorate. [R] [216901]

Mr. Bradshaw [holding answer 7 July 2008]: The Director General of the Commercial Directorate is in post until 15 July 2008. The Department remains committed to having strong commercial expertise and presence in its leadership team and decisions will be taken in due course on appropriate leadership arrangements. In the interim, Director General level leadership for the directorate will be provided by the Director General for Commissioning and System Management.

NHS: Telephone Services

Mike Penning: To ask the Secretary of State for Health pursuant to the Answer of 16 June 2008, Official Report, column 766W, on NHS: telephone service, what the reasons are for the disparity between calls to NHS Direct (a) made and (b) forecast in (i) 2006-07 and (ii) 2007-08. [216083]

Mr. Bradshaw: The reasons for the differences between the number of calls forecast and number of calls made in 2006-07 and 2007-08 are as follows:


14 July 2008 : Column 208W

Regulatory Impact Assessments

Mr. Amess: To ask the Secretary of State for Health what criteria are used by his Department to determine whether a regulatory impact assessment should be undertaken on primary legislation; and if he will make a statement. [216402]

Mr. Bradshaw: Regulatory impact assessments no longer exist as they have been superseded by impact assessments. The Department follows the criteria contained in guidance provided by the Department for Business, Enterprise and Regulatory Reform (BERR). Impact assessments are required:

However, a proportionate approach should be used. If the cost of a proposal is below £5 million only a developmental/option stage impact assessment is necessary.

Further information is available on BERR website at:

Smoking: Young People

David Taylor: To ask the Secretary of State for Health what assessment he has made of the effects of (a) tobacco advertising and promotion and (b) displays of tobacco at the point of sale on young people's smoking behaviour; and what research has been conducted into each of these areas. [218367]

Dawn Primarolo: The Government's recently published ‘A consultation on the Future of Tobacco Control’ includes an overview of research on tobacco marketing and promotion and young people, and asks several questions of stakeholders in this area.

Copies of the consultation have already been placed in the Library.


14 July 2008 : Column 209W

David Taylor: To ask the Secretary of State for Health what research his Department has undertaken or evaluated on how under 18 year-olds obtain tobacco products. [218368]

Dawn Primarolo: Protecting young people from smoking is a priority for the Government, and is one of the key areas of the Department's current consultation on the future of tobacco control, ‘A consultation on the Future of Tobacco Control’. Copies of the consultation have already been placed in the Library. The age of sale for tobacco was raised to 18 years on 1 October 2007. Tougher sanctions against retailers who persistently flout the tobacco age of sale law will be introduced in April 2009.

Latest information about the sources of tobacco for children who regularly smoke is published by The Information Centre for health and social care in ‘Smoking, Drinking and Drug Use Amongst Young People in England 2006’. Copies of this information have already been placed in the Library.

Social Care Journal

Mr. Stephen O'Brien: To ask the Secretary of State for Health what discussions he has had with publishers on the implementation of the recommendation of the Platt Review on the establishment of a social care journal. [213330]

Mr. Ivan Lewis: The Department has commissioned the Social Care Institute for Excellence (SCIE) to take forward this project on its behalf. In the first phase of work, the SCIE commissioned strategic consultancy from the Central Office of Information to develop options for a new journal. A report on the outcome of this work was submitted to the Department in March 2008.

The second phase will be a formal process of engagement/tendering, between January and March 2009, to identify an appropriate commercial partner.

Southern Cross Healthcare: Care Homes

John McDonnell: To ask the Secretary of State for Health (1) if he will take steps to investigate the reports by Southern Cross Healthcare that it is experiencing
14 July 2008 : Column 210W
higher than normal attrition rates in its residential care homes; [216807]

(2) what contingency planning the Government have undertaken to ensure the continuance of care for the elderly in the event of Southern Cross Healthcare being unable to continue in operation as a result of its financial difficulties. [216808]

Mr. Ivan Lewis: We have been informed by the Commission for Social Care Inspection (CSCI) that it monitors care homes individually and would take action on any such information received. Regulation 37 Notification of deaths, illness and other events, of the Care Homes Regulations 2001 requires homes to notify CSCI "without delay of the occurrence of (a) the death of any service user, including the circumstances of his death".

There have been no concerns raised with local CSCI offices or inspectors in respect of this issue regarding Southern Cross care homes.

Local authorities are responsible for managing and directing their resources in accordance with local priorities and the needs of the communities to which they are accountable. This will include ensuring continuity of care to residents for whose care they are responsible.

St Mary's Hospital NHS Trust: Waiting Lists

Ms Buck: To ask the Secretary of State for Health what the median waiting time in weeks was at St. Mary's NHS Trust for (a) ordinary admissions, (b) first out-patient attendance from GP referral and (c) day case admission in each year since 2007. [216474]

Mr. Bradshaw: Information is not held in the format requested. Data are no longer collected separately for ordinary and day case admissions but are combined for patients waiting for admission to hospital. In addition, St. Mary's NHS Trust merged with Hammersmith Hospitals NHS Trust on 30 September 2007 to form Imperial College Healthcare NHS Trust.

The following table shows the median waiting times for inpatient admission and first outpatient attendance at St. Mary's NHS Trust and Hammersmith Hospitals NHS Trust at 31 March 2007 and at Imperial College Healthcare NHS Trust at 31 March 2008 and 31 May 2008. This is the latest information that is available.

Median waiting time for inpatient admission and first outpatient attendance (weeks)

Organisation Inpatient Outpatient

Period ending 31 March 2007

St. Mary's NHS Trust

5.3

3.3

Hammersmith Hospitals NHS Trust

5.9

3.4

Trusts Combined

5.6

3.4

Period ending 31 March 2008

Imperial College Healthcare NHS Trust

3.9

2.5

Period ending May 2008

Imperial College Healthcare NHS Trust

3.1

2.2

Notes:
1. Median waiting times are calculated from aggregate data, rather than patient level data, and therefore are only estimates of the position on average waits. This should be taken into account when interpreting the data.
2. The inpatient figures show the median waiting times for patients still waiting for admission at the end of the period stated. Inpatient waiting times are measured from decision to admit by the consultant to admission to hospital.
3. The outpatient figures show the median waiting times for patients still waiting for a first outpatient appointment following a general practitioner (GP) referral at the end of the period stated. Outpatient waiting times are measured from a GP referral to a first outpatient appointment with the consultant.
Source:
Monthly Monitoring Return—provider based.

14 July 2008 : Column 211W

Vaccination

Ian Stewart: To ask the Secretary of State for Health which manufacturers have supplied vaccines to the
14 July 2008 : Column 212W
NHS; over what period of time each vaccine was supplied; and if he will make a statement. [216715]

Dawn Primarolo: The information requested is shown in the following table.


14 July 2008 : Column 213W

14 July 2008 : Column 214W
Vaccine Manufacturer/brand name Start Finish

Acellular Pertussis Vaccine (APV)

Lederle—APV

May 1994

August 2000

Anthrax

The Health Protection Agency—Anthrax

September 2004

Ongoing

Bacilllus Calmette Guerin (BCG)

Evans vaccine—BCG (Intradermal)

1986

August 2002

BCG

Evans vaccine—BCG (Percutaneous)

1992

June 2005

BCG

Statens Serum Institut—BCG (Intradermal)

December 2002

Ongoing

Diphtheria and Tetanus (DT)

Aventis Pasteur MSD—different dosages—DT

1992

July 2003

DT

Chiron Vaccines—DT

April 2000

January 2004

DT

Medeva—DT

1992

March 1999

Diphtheria (D)

Medeva—Diphtheria

April 1993

June 2000

Diphtheria, Tetanus and Acellular Pertussis (DTaP)

GlaxoSmithKline—Infanrix

October 2001

October 2004

Diphtheria, Tetanus and Wholecell Pertussis (DTwP)

Aventis Pasteur MSD—DTP

1994

June 2000

DTwP

Chiron Behring—DTP

1998

January 2003

DTwP

Medeva—Trviax AD

1992

November 1998

Diphtheria, Tetanus, Acellular Pertussis and Inactivated Polio (DTaP/IPV)

Aventis Pasteur MSD—Tetravax

April 2001

July 2001

DTaP/IPV

GlaxoSmithKline—Infanrix IPV

February 2005

Ongoing

DTaP/IPV

Sanofi Pasteur MSD—Repevax

August 2004

Ongoing

Diphtheria, Tetanus, Acellular Pertussis and Inactivated Polio with Haemophilus influenzae type b (DTaP/IPV+Hib)

GlaxoSmithKline—Infanrix/IPV+Hib

March 2006

Ongoing

DTaP/IPV+Hib

Sanofi Pasteur MSD—Pediacel

August 2004

Ongoing

Haemophilus influenzae type b (Hib)

Aventis Pasteur MSD—ACT Hib

1992

April 2002

Hib

GlaxoSmithKline—Hiberix

June 2001

July 2006

Hib

Lederle—HibTITER

1992

2001

Haemophilus influenzae type b/Meningococcal Group C Conjugate (Hib/Men C)

GlaxoSmithKline—Menitorix

July 2007

Ongoing

Haemophilus influenzae type b with Diphtheria, Tetanus and Acellular Pertussis (DTaP/Hib)

GlaxoSmithKline—Infanrix Hib

December 1999

February 2003

Haemophilus influenzae type b with Diphtheria, Tetanus and Wholecell Pertussis (DTwP/Hib)

Aventis Pasteur MSD—ACTHib DTP

April 1996

September 2004

DTwP/Hib

SmithKlineBeecham—Trivax/Hib

May 1997

October 1999

Inactivated Polio (IPV)

Aventis Pasteur MSD—Inactivated polio

1984

October 2004

Low Dose Diphtheria (d)

Berna Biotech—Low Dose Diphtheria

October 1995

August 2003

Measles, mumps and rubella (MMR)

GlaxoSmithKline—Priorix

May 1998

Ongoing

MMR

Pasteur Merieux—Immravax

1989-90

1992-93

MMR

Sanofi Pasteur MSD—MMR II

April 1998

Ongoing

MMR

Sanofi Pasteur MSD—MMR II (American MMR)

May 2005

July 2005

MMR

Sanofi Pasteur MSD—Triplovax (German MMR)

May 2005

June 2005

MMR

SmithKlineBeecham—Pluserix

1988-89

1992-93

Meningoccocal Group C Conjugate (MenC)

Baxter Healthcare—Neisvac

August 2000

January 2007

MenC

Chiron vaccines—Menjugate

March 2000

March 2005

MenC

Novartis vaccines—Menjugate Kit

April 2006

Ongoing

MenC

Wyeth vaccines—Meningitec

October 1999

September 2007

Oral Polio (OPV)

Evans Vaccines—Oral Polio

December 1998

October 2000

OPV

GlaxoSmithKline—Oral polio

April 2001

October 2004

OPV

SmithKilneBeecham—Oral Polio

April 1997

March 2001

Pneumococcal conjugate (PCV)

Wyeth—Prevenar

April 2006

Ongoing

Rabies

Rabies vaccine has been purchased for the NHS since 1979 from either Sanofi Pasteur MSD or Novartis Vaccines

1979

Ongoing

Rubella

Evans—Almevax

1992

1997

Rubella

SmithKlineBeecham—Ervevax

1992

2003

Tetanus and Low Dose Diphtheria (Td)

Aventis Pasteur MSD—Diftavax

September 1994

November 2006

Tetanus and Low Dose Diphtheria with Inactivated Polio (Td/IPV)

Sanofi Pasteur MSD—Revaxis

August 2004

Ongoing

Tuberculin Purified Protein Derivative (PPD) (diagnostic test for tuberculosis (TB))

Chiron vaccines—10 unit

1986

May 2005

Tuberculin PPD (diagnostic test for TB)

Chiron vaccines—100 unit

1992

May 2005

Tuberculin PPD (diagnostic test for TB)

Chiron vaccines—1,000 unit

1992

May 2005

Tuberculin PPD (diagnostic test for TB)

Chiron vaccines—Heaf test

1986

November 2005

Tuberculin PPD (diagnostic test for TB)

Statens Serum Institut—SS2

July 2005

Ongoing

Tuberculin PPD (diagnostic test for TB)

Statens Serum Institut—SSI0

May 2005

Ongoing


Next Section Index Home Page